Immunoprecise Antibodies Ltd (IPA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunoprecise Antibodies Ltd (IPA) has a cash flow conversion efficiency ratio of -0.048x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($23.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Immunoprecise Antibodies Ltd for the company's overall valuation and market capitalisation.
Immunoprecise Antibodies Ltd - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Immunoprecise Antibodies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunoprecise Antibodies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunoprecise Antibodies Ltd ranked by their cash flow conversion efficiency. Explore IPA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uno&Company.Ltd
KQ:114630
|
0.013x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
-0.041x |
|
Apex Biotechnology Corp
TW:1733
|
0.003x |
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
0.013x |
|
KGL Resources Ltd
AU:KGL
|
-0.009x |
|
Miwon Holdings Co. Ltd
KO:107590
|
0.012x |
|
Microbot Medical Inc
NASDAQ:MBOT
|
-0.068x |
Annual Cash Flow Conversion Efficiency for Immunoprecise Antibodies Ltd (1997–2025)
The table below shows the annual cash flow conversion efficiency of Immunoprecise Antibodies Ltd from 1997 to 2025. View Immunoprecise Antibodies Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -160.37% |
| 2022-04-30 | $75.28 Million | $-9.92 Million | -0.132x | -1150.23% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +318.14% |
| 2011-04-30 | $158.40K | $-80.39K | -0.507x | -793.11% |
| 2010-04-30 | $5.43 Million | $-308.49K | -0.057x | -147.62% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -86.65% |
| 2007-04-30 | $5.43 Million | $-297.31K | -0.055x | -93.48% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +33.99% |
| 2003-04-30 | $867.54K | $-168.38K | -0.194x | +52.10% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more